

Anti-Cancer Drugs 2006

Author Index to Volume I7

- aan de Wiel-Ambagtsheer G. *See* Hoving S, 949
- Abad A. *See* Sastre J, 417
- Abemayor E. *See* St John MAR, 365
- Adedayo O. *See* Hasinoff BB, 825
- Agostara B. *See* Nisticò C, 345
- Agresti B. *See* Livi L, 1081
- Aguirre G. *See* Fuentes H, 565
- Ahmad I. *See* Chen P, 53
- Ahmad MU. *See* Chen P, 53
- Ahmed-Belkacem A *et al.* Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2), 239
- Aisa Y. *See* Mori T, 597
- Akiyama K. *See* Fukuda Y, 943
- Åleskog A. *See* Olsson-Strömberg U, 631
- Alexander F. *See* Fuentes H, 565
- Alfo M. *See* De Sanctis V, 967
- Ali SM. *See* Chen P, 53
- Allievi C. *See* Hensing TA, 697
- Alonso M. *See* Barceló R, 89
- Alonso-Varona A. *See* Palomares T, 1219
- André N. *See* Milano E, 1231
- Angelucci A *et al.* Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways, 1141
- Annabi B *et al.* Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling, 429
- Aoki S *et al.* Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells, 269
- Apte SP. *See* Sarangarajan R, 21
- Arai M. *See* Mori T, 597
- Aranda E. *See* Sastre J, 417
- Arango D. *See* Bressin C, 181
- Arita S. *See* Qin B, 439; *also* Qin B, 445
- Ariyama H. *See* Qin B, 439; *also* Qin B, 445
- Arnaud P. *See* Decaudin D, 685
- Arsenou ES. *See* Fousteris MA, 511
- Aubert C. *See* Fanciullino R, 465
- Au-Yeung SCF. *See* To KKW, 673
- Avila E. *See* Fuentes H, 565
- Avolio T. *See* Lee Y, 143
- Awada A. *See* Kasper B, 1223
- Azarnia N. *See* Batist G, 587
- Azizi E. *See* Mousavi-Shafaei P, 1031
- Baba E. *See* Qin B, 439; *also* Qin B, 445
- Bacchini P. *See* Bacci G, 411
- Bacci G *et al.* No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma, 411
- Bailly C. *See* Kluza J, 155
- Bakker WH. *See* Engels FK, 63
- Balcells M. *See* Barceló R, 89
- Balduzzi A. *See* Orlando L, 956
- Banelli E. *See* De Sanctis V, 967
- Bang S-M. *See* Park SH, 225
- Barbany G. *See* Olsson-Strömberg U, 631
- Barceló R *et al.* Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer, 89
- Barni S. *See* Nisticò C, 345
- Barra Y. *See* Bressin C, 181
- Barrett CM. *See* Lothstein L, 495
- Basile M. *See* Milano A, 869
- Batist G *et al.* Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis, 587
- Battastini AMO. *See* Braganhol E, 663
- Baumann F. *See* Preiss R, 75
- Baumann P. *See* Schmidmaier R, 621
- Bednarski PJ. *See* Bracht K, 41
- Beer TM *et al.* Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study, 1075
- Béliveau R. *See* Annabi B, 429
- Bellarosa D. *See* Binaschi M, 1119
- Bello CL *et al.* Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects, 353
- Bengtsson M. *See* Olsson-Strömberg U, 631
- Benider A. *See* Petit T, 337
- Benoit L. *See* Molucon-Chabrot C, 1211
- Bensaoula O. *See* Bethune-Volters A, 217
- Bergqvist M. *See* Dreilich M, 503
- Bernardini S. *See* Angelucci A, 1141
- Bertaux Brigitte. *See* Petit T, 337
- Bertelli AAE. *See* Gagliano N, 189
- Bertoni F. *See* Bacci G, 411
- Bethune-Volters A *et al.* A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis, 217
- Beuzeboc P. *See* Fléchon A, 705
- Bhat G. *See* Beer TM, 1075
- Bigioni M. *See* Binaschi M, 1119
- Bilbao P. *See* Palomares T, 1127
- Binaschi M *et al.* Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate, 1119
- Birmingham A. *See* Engman L, 539
- Biti G. *See* Livi L, 1081
- Björnberg A. *See* Olsson-Strömberg U, 631
- Blüthner T. *See* Wiedmann M, 783
- Boeck S. *See* Fahrigr R, 1045
- Boga C. *See* Pagnotta E, 521
- Bologna Mauro. *See* Angelucci A, 1141
- Bolognesi C. *See* Nersesyan A, 289
- Bonhomme-Faivre L. *See* Hosten B, 195
- Bonner JA. *See* Dobelbower MC, 95
- Boos J. *See* Lanvers-Kaminsky C, 657; *also* Wagner-Bohn A, 859; *also* Lanvers-Kaminsky C, 1025
- Bordier V. *See* Decaudin D, 685
- Borghesi S. *See* Livi L, 1081

- Borrow JM. *See* Yu F, 1151
- Borstnar S. *See* Piskur P, 719
- Bottaro DP. *See* Dharmawardana PG, 13
- Boubakari. *See* Bracht K, 41
- Bougnoux P. *See* Petit T, 337
- Boulikas T. *See* Fedier André, 315
- Boumendjel A. *See* Ahmed-Belkacem A, 239
- Bouquet C. *See* Hosten B, 195
- Bourgarel-Rey V. *See* Bressin C, 181
- Bouvier C. *See* Milano E, 1231
- Bouzeghrane M. *See* Annabi B, 429
- Bracht K *et al.* Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data, 41
- Braganhol E *et al.* Antiproliferative effect of quercetin in the human U138MG glioma cell line, 663
- Braguer D. *See* Bressin C, 181; *also* Milano E, 1231
- Brahimi F. *See* Merayo N, 165
- Brattström D. *See* Dreilich M, 503
- Bredius RGM. *See* Zwaveling J, 1099
- Breidenbach M. *See* Hille S, 1041
- Bremer A. *See* Lanvers-Kaminsky C, 657
- Bressin C *et al.* Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine, 181
- Bria E. *See* Nisticò C, 345; *also* Nisticò C, 1193
- Briasoulis E *et al.* Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction, 1219
- Brienza S. *See* Petit T, 337; *also* Delozier T, 1067
- Britt-Marie F. *See* Palle J, 1087
- Brown S. *See* Duran I, 81
- Budman DR *et al.* Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis, 921
- Buijs D. *See* Engels FK, 63
- Burke TR. *See* Dharmawardana PG, 13
- Caca K. *See* Wiedmann M, 783
- Cai Y-C. *See* Li J-L, 307; *also* Shan H-b, 905; *also* Li J-L, 1107
- Calabro A. *See* Budman DR, 921
- Calderillo G. *See* Fuentes H, 565
- Calonghi N. *See* Pagnotta E, 521
- Camboni MG. *See* Hensing TA, 697
- Canedo AD. *See* Braganhol E, 663
- Caponigro F. *See* Milano A, 869
- Carbone C. *See* Ferrari D, 359
- Cardile V. *See* Russo A, 1163
- Cardillo A. *See* Orlando L, 956
- Cardillo CDL. *See* Livi L, 1081
- Carrato A. *See* Sastre J, 417
- Carré M. *See* Bressin C, 181
- Casal J. *See* Grande C, 1
- Casaretti R. *See* Comella P, 985
- Castañón C. *See* Barceló R, 89
- Castro B. *See* Palomares T, 1127
- Cattan S. *See* Hebbar M, 855
- Cattaneo A. *See* Rende M, 929
- Cekanova M *et al.* Pulmonary fibroblasts stimulate the proliferation of cell lines from human lung adenocarcinomas, 771
- Centelles M. *See* Barceló R, 89
- Challuau D. *See* Hosten B, 195
- Chang Y-C. *See* Liu C-L, 709
- Chauffert B. *See* Molucon-Chabrot C, 1211
- Chen EX. *See* Duran I, 81
- Chen F-M. *See* Tong Q-S, 279
- Chen H. *See* Kunnimalaiyaan M, 139; *also* Wang D-M, 527; *also* Vaccaro A, 849
- Chen H-x. *See* Shan H-b, 905
- Chen P *et al.* In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate, 53
- Chen S. *See* Tian Z, 545
- Chen T *et al.* Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?, 123
- Chen X. *See* Kong W-J, 251
- Cheng S-P. *See* Liu C-L, 709
- Chevreau C. *See* Fléchon A, 705
- Chidiac J. *See* Bethune-Volters A, 217
- Chien P-Y. *See* Chen P, 53
- Chin K. *See* Sakamoto J, 231
- Chin SF. *See* Duran I, 81
- Chiofalo MG. *See* Milano A, 869
- Cho EK. *See* Park SH, 225
- Cho S-h. *See* Aoki S, 269
- Cho Y-B. *See* Lee J-W, 377
- Choi J *et al.* Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer, 103
- Chollet P. *See* Delozier T, 1067
- Chow WA *et al.* Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1, 891
- Chung M. *See* Park SH, 225
- Ciccolini J. *See* Fanciullino R, 465; *also* Fischel J-L, 807
- Cinieri S. *See* Orlando L, 956
- Clemons LK. *See* Dobelbower MC, 95
- Codecà C. *See* Ferrari D, 359
- Coeffic D. *See* Delozier T, 1067
- Cognetti F. *See* Nisticò C, 1193
- Colella E. *See* Nisticò C, 345
- Colleoni M. *See* Orlando L, 956; *also* Rocca A, 1201
- Comella P *et al.* Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer, 985
- Conroy M. *See* Fernando A, 913
- Conti M *See* Cyclopentenone: a special moiety for anticancer drug design, 1017
- Coudert B. *See* Molucon-Chabrot C, 1211
- Courssaris B. *See* Lee Y, 143
- Couturier J. *See* Decaudin D, 685
- Coze C. *See* Milano E, 1231
- Crea A. *See* Binaschi M, 1119
- Cree IA. *See* Knight LA, 649; *also* Fernando A, 913
- Cufer T *et al.* Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer, 401; *also see* Piskur P, 719
- Culine S. *See* Fléchon A, 705
- Cuppone F. *See* Nisticò C, 345; *also* Nisticò C, 1193
- Cuq P. *See* Fanciullino R, 465
- Curigliano G. *See* Rocca A, 1201
- Currie J-C. *See* Annabi B, 429
- Cvitkovic E. *See* Petit T, 337; *also* Delozier T, 1067
- Dahut WL. *See* Lakhani N, 977
- Daigneault L. *See* Annabi B, 429
- D'Alessandro C. *See* Orlando L, 956
- Daza-Ramirez P. *See* Batist G, 587
- de Anta JM *et al.* The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance, 1171
- de Bruijn EA. *See* Hoving S, 949
- de Luna AS. *See* Milano A, 869

- Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

- Freudlsperger C *et al.* Anti-proliferative effect of peroxisome proliferator-activated receptor γ agonists on human malignant melanoma cells *in vitro*, 325
- Frontini L. *See* Nisticò C, 345
- Frost B-M. *See* Palle J, 385
- Fuentes H *et al.* Phase II study of gemcitabine plus cisplatin in metastatic breast cancer, 565
- Fujisawa M. *See* Hara I, 1057
- Fujita T *et al.* Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells, 455
- Fuke H. *See* Inoue T, 261
- Fukuda Y *et al.* The anti-tumor effect of *Euchema serra* agglutinin on colon cancer cells *in vitro* and *in vivo*, 943
- Fukuta Y. *See* Fukuda Y, 943
- Fumagalli L. *See* Ferrari D, 359
- Fumoleau P. *See* Molucon-Chabrot C, 1211
- Funk G. *See* Wenzel C, 865
- Furukawa J. *See* Hara I, 1057
- Furukawa N. *See* Takekuma M, 715
- Gaafar R. *See* Cufer T, 401
- Gagliano N *et al.* Effect of Ukrain on matrix metalloproteinase-2 and Secreted Protein Acidic and Rich in Cysteine (SPARC) expression in human glioblastoma cells, 189
- Gajewska M. *See* Engman L, 539
- Gibaldi A. *See* Livi L, 1081
- Gallardo D. *See* Fuentes H, 565
- Gallego J. *See* Sastre J, 417
- Gao J-Q. *See* Aoki S, 269
- Garbarino J. *See* Russo A, 1163
- García Girón C. *See* Barceló R, 89
- Garde S. *See* Annabi B, 429
- Garnick M. *See* Beer TM, 1075
- Gavilli S. *See* Livi L, 1081
- Geoffrois L. *See* Fléchon A, 705
- George JA. *See* Chen T, 123
- Georgoulas V. *See* Pappas P, 1185
- Gerssß J. *See* Wagner-Bohn A, 859
- Ghisini R. *See* Orlando L, 956; *also* Rocca A, 1201
- Giacometti S. *See* Fanciullino R, 465
- Giannarelli D. *See* Nisticò C, 1193
- Gibassier J. *See* Massart C, 559
- Giessler C. *See* Weiss M, 69
- Gil S. *See* Hosten B, 195
- Gil T. *See* Kasper B, 1223
- Gilardi L. *See* Ferrari D, 359
- Gillenwater HH. *See* Hensing TA, 697
- Gioia M. *See* Gagliano N, 189
- Giovanardi F. *See* Rocca A, 1201
- Giubellino A. *See* Dharmawardana PG, 13
- Glasyher S. *See* Knight LA, 649; *also* Fernando A, 913
- Goldberg ID. *See* Ma Y, 733
- Goldhirsch A. *See* Orlando L, 956; *also* Rocca A, 1201
- Gómez A. *See* Sastre J, 417
- Goodfellow V. *See* Hasinoff BB, 825
- Göran G. *See* Palle J, 1087
- Gorincour G. *See* Milano E, 1231
- Goso C. *See* Binaschi M, 1119
- Gotlib V *et al.* Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response, 1227
- Gourgou-Bourgade S. *See* Fléchon A, 705
- Grande C *et al.* Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma, 1
- Gravina GL. *See* Angelucci A, 1141
- Greenman J. *See* Lam T, 113
- Grünert R. *See* Bracht K, 41
- Gu H. *See* Wang W, 797
- Guastalla J-P. *See* Delozier T, 1067
- Guchelaar H-J. *See* Zwaveling J, 1099
- Gudmar L. *See* Palle J, 1087
- Guilland J-C. *See* Molucon-Chabrot C, 1211
- Guo C-K. *See* Kong W-J, 251
- Guo Q. *See* Wang W, 797
- Guo S. *See* Chow WA, 891
- Gustafsson G. *See* Palle J, 385
- Hamma-Kourbali Y. *See* Ledoux D, 479
- Han SH. *See* Park SH, 225
- Hänel M. *See* Fahrigr R, 1045
- Hanigan MH. *See* Shord SS, 207
- Hanna NH. *See* Hensing TA, 697
- Hara I *et al.* Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience, 1057
- Harada M. *See* Qin B, 439; *also* Qin B, 445
- Harris L. *See* Batist G, 587
- Hartley JA. *See* Kluza J, 155
- Hartmann JT. *See* Kopp H-G, 997
- Hashmi S. *See* Wasif Saif M, 1095
- Hasinoff BB *et al.* Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects, 825
- Haupt S *et al.* Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species, 609; *also* Importance of p53 for cancer onset and therapy, 725; *also see* Haupt S, 609; *also see* Haupt S, 725
- Hayashi Y. *See* Nicholson B, 25
- He H. *See* Liu X, 173
- He Q *et al.* Antileukemia activity of MSFTZ-a novel flavanone analog, 641
- He Y. *See* Xiang D, 753
- Hebbbar M *et al.* Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer, 855
- Hegele A. *See* Olbert P, 993
- Heidenreich A. *See* Olbert P, 993
- Heider U. *See* Eucker J, 763
- Heinemann V. *See* Fahrigr R, 1045
- Heinrich J-C. *See* Fahrigr R, 1045
- Hellebostad M. *See* Palle J, 385
- Hensing TA *et al.* Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer, 697
- Hersey Peter. *See* Yu F, 1151
- Hersh E. *See* Pourpak A, 1179
- Hetherington JW. *See* Lam T, 113
- Higuchi K. *See* Sasaki T, 581
- Hille S *et al.* Anticancer drugs induce *mdr1* gene expression in recurrent ovarian cancer, 1049
- Hirashima Y. *See* Takekuma M, 715
- Ho Y-P. *See* To KKW, 673
- Hofmann R. *See* Olbert P, 993
- Höglund M. *See* Olsson-Strömberg U, 631
- Holcombe RF. *See* Choi J, 103
- Horn F. *See* Braganhol E, 663
- Hosten B *et al.* Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma, 195
- Hoving S *et al.* Early destruction of tumor vasculature in tumor

- necrosis factor- α -based isolated limb perfusion is responsible for tumor response, 949
- Hu C. *See* Ma Y, 733
- Hu Y. *See* He Q, 641; *also* Wang W, 797
- Huang B-R. *See* Wang D-M, 527
- Huang F. *See* Tian Z, 545
- Huang J-K. *See* Liu C-L, 709
- Hungerford JL. *See* Knight LA, 649
- Hurren J. *See* Knight LA, 649
- Hyodo I. *See* Sakamoto J, 231
- Iglesias A. *See* Palomares T, 1127
- Ikeda Y. *See* Mori T, 597
- Inoue T *et al.* Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway, 261
- Intra M. *See* Rocca A, 1201
- Irwin H. *See* Kluza J, 155
- Isambert N. *See* Molucon-Chabrot C, 1211
- Israel M. *See* Lothstein L, 495
- Ito I. *See* Takekuma M, 715
- Ito K. *See* Inoue T, 261
- Izzo F. *See* Nisticò C, 345; *also* Comella P, 985
- Jakob C. *See* Eucker J, 763
- Jean-Claude BJ. *See* Merayo N, 165
- Jiang F-c. *See* Tong Q-S, 279
- Jin H. *See* Lee Y, 143
- Jukka K. *See* Palle J, 1087
- Jürgens H. *See* Lanvers-Kaminsky C, 657
- Kaiser M. *See* Eucker J, 763
- Kamano T. *See* Tsuruoka Y, 393
- Kamenz T. *See* Wiedmann M, 783
- Kanazawa S *et al.* Aspirin reduces adverse effects of gefitinib, 423
- Kanerva J. *See* Palle J, 385
- Kang W. *See* Weiss M, 69
- Kanz L. *See* Kopp H-G, 997
- Karavasilis V. *See* Briasoulis E, 1219
- Kasper B *et al.* Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp, 1223
- Kato K. *See* Fukuda Y, 943
- Kawai K. *See* Tsuruoka Y, 393
- Kawakubo A. *See* Fukuda Y, 943
- Kawasaki K. *See* Fujita T, 455
- Kenneth Lloyd G. *See* Nicholson B, 25
- Kepler CY. *See* Pourpak A, 1179
- Khaled S. *See* Gotlib V, 1227
- Khan AR. *See* Chen P, 53
- Kim K-H. *See* Kwon Y-E, 553
- Kim S-Y. *See* Lee J-W, 377
- Kinoshita Y. *See* Kanazawa S, 423
- Kirby R and Offen N. Managing locally advanced prostate cancer: a urologist's and a patient's perspective, 245
- Kiso Y. *See* Nicholson B, 25
- Kitajima M. *See* Tsuruoka Y, 393
- Kjeld S. *See* Palle J, 1087
- Klamerus KJ. *See* Bello CL, 353
- Kleinstern J. *See* Haupt S, 609
- Kluge A. *See* Wiedmann M, 783
- Kluza J *et al.* Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide, 155
- Knight LA *et al.* The effect of imatinib mesylate (Glivec) on human tumor-derived cells, 649; *also see* Fernando A, 913
- Kobayashi M. *See* Aoki S, 269
- Koizumi W. *See* Sakamoto J, 231; *also* Sasaki T, 581
- Kojima H. *See* Sakamoto J, 231
- Komiyama Y. *See* Kanazawa S, 423
- Kondo K. *See* Sakamoto J, 231
- Kong K. *See* Choi J, 103
- Kong W. *See* Kong W-J, 251
- Kong W-J *et al.* Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma, 251
- Kopp H-G *et al.* Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide, 997
- Kornek GV. *See* Wenzel C, 865
- Köster J. *See* Lanvers-Kaminsky C, 1025
- Koukourakis MI and Maltezos E. Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases, 133
- Koutsourea AI. *See* Foustieris MA, 511
- Kraemer M. *See* Ledoux D, 479
- Kraeuter P. *See* Olbert P, 993
- Krebbel H. *See* Eucker J, 763
- Krempl GA. *See* Shord SS, 207
- Krenning EP. *See* Engels FK, 63
- Kroutil A. *See* Sova P, 201
- Krupitza G. *See* Fahrig R, 1045
- Kuh H-J. *See* Lee J-W, 377
- Kumano M. *See* Hara I, 1057
- Kumar S. *See* Engman L, 539
- Kunnimalaiyaan M and Chen H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?, 139; *also see* Vaccaro A, 849
- Kurbacher CM. *See* Hille S, 1041
- Kusaba H. *See* Qin B, 439; *also* Qin B, 445
- Kuwano M. *See* Aoki S, 269
- Kuwano T. *See* Aoki S, 269
- Kvols LK and Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors, 601
- Kwon Y-E and Kim K-H. Octahedral Pt(IV) complex K101 induces apoptosis via ERK1/2 activation and the p53 pathway in human colon cancer cells, 553
- Lakhani N *et al.* Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol, 977
- Lam T *et al.* From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials, 113
- Lamont A. *See* Knight LA, 649
- Lankester AC. *See* Zwaveling J, 1099
- Lantz O. *See* Decaudin D, 685
- Lanvers-Kaminsky C *et al.* Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines, 657; *also* In-vitro toxicity of Ukrain against human Ewing tumor cell lines, 1025
- Lapko I. *See* Gotlib V, 1227
- Larsson R. *See* Olsson-Strömberg U, 631
- Laterra JJ. *See* Ma Y, 733
- Laufer RS. *See* Hasinoff BB, 825
- Lecouvey M. *See* Ledoux D, 479
- Ledoux D *et al.* A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice, 479
- Lee J. *See* Wu X-H, 839
- Lee JH. *See* Park SH, 225
- Lee J-J. *See* Liu C-L, 709
- Lee J-W *et al.* Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells *in vitro*, 377
- Lee L. *See* Batist G, 587

- Lee S-H. *See* Lee J-W, 377
 Lee WK. *See* Park SH, 225
 Lee Y *et al.* Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin, 143; *also see* Park SH, 225
 Levy C. *See* Delozier T, 1067
 Li G. *See* Tang L, 297
 Li J-L *et al.* Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells, 307; *also* Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells, 1107
 Li R. *See* He Q, 641
 Li Z. *See* Xiang D, 753
 Liebert A. *See* Fahrig R, 1045
 Lindhagen E. *See* Olsson-Strömberg U, 631
 Lindkvist A. *See* Dreilich M, 503
 Lipovová P. *See* Škvor J, 815
 Liu C-L *et al.* Fatty liver and transaminase changes with adjuvant tamoxifen therapy, 709
 Liu T-P. *See* Liu C-L, 709
 Liu W. *See* Wang W, 797
 Liu X *et al.* Difference of cell cycle arrests induced by lidamycin in human breast cancer cells, 173
 Liu X-H. *See* Li J-L, 307; *also* Shan H-b, 905; *also* Li J-L, 1107
 Liu Y. *See* Shan H-b, 905
 Liu Z. *See* Kong W-J, 251
 Livi L *et al.* Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer, 1081
 Lombardo L. *See* Russo A, 1163
 Longhi A. *See* Bacci G, 411
 Loos WJ. *See* Engels FK, 63
 López E. *See* Sastre J, 417
 Loro L. *See* Bacci G, 411
 Lossignol D. *See* Kasper B, 1223
 Lothstein L *et al.* N-benzyladriamycin-14-valerate (AD 198) activates protein kinase C- α holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca²⁺ influx, 495
 Lu P. *See* Tong Q-S, 279
 Luini A. *See* Rocca A, 1201
 Lynch AR. *See* Santen RJ, 33
 Ma X-L. *See* Wang D-M, 527
 Ma Y *et al.* Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum, 733
 Macalou S. *See* Ahmed-Belkacem A, 239
 Maggi C. *See* Binaschi M, 1119
 Magnani I. *See* Gagliano N, 189
 Mahyar-Roemer M. *See* Pöhlend T, 471
 Maindault-Goebel Frédérique. *See* Petit T, 337
 Maisonneuve P. *See* Rocca A, 1201
 Majidi M. *See* Cekanova M, 771
 Makarem JA. *See* El-Saghir NS, 999
 Maltezos E. *See* Koukourakis MI, 133
 Manzano J. *See* Sastre J, 417
 Manzini S. *See* Binaschi M, 1119
 Mar N. *See* Gotlib V, 1227
 Maraveyas A. *See* Lam T, 113
 Marion S. *See* Hosten B, 195
 Marit H. *See* Palle J, 1087
 Marselos M. *See* Pappas P, 1185
 Marszak F. *See* Decaudin D, 685
 Martin A. *See* Decaudin D, 685
 Marussi D. *See* Ferrari D, 359
 Masi T. *See* Cekanova M, 771
 Masotti L. *See* Pagnotta E, 521
 Massart C *et al.* Effect of all-trans retinoic acid and sodium butyrate *in vitro* and *in vivo* on thyroid carcinoma xenografts, 559
 Massidda B. *See* Comella P, 985
 Masuda S. *See* Fukuda Y, 943
 Mathiot C. *See* Decaudin D, 685
 Matoušek J. *See* Škvor J, 815
 Matthias M. *See* Preiss R, 75
 Mattison L. *See* Wasif Saif M, 1095
 Mavroudis D. *See* Pappas P, 1185
 Mayer F. *See* Molucon-Chabrot C, 1211
 Mayol X. *See* de Anta JM, 1171
 Mayumi T. *See* Aoki S, 269
 Mazinghien R. *See* Kluza J, 155
 Mazzarella G. *See* De Sanctis V, 967
 McNaughton M. *See* Engman L, 539
 McPherson RA. *See* Santen RJ, 33
 Meinhardt G. *See* Schmidmaier R, 621
 Merayo N *et al.* The combi-targeting concept: evidence for the formation of a novel inhibitor *in vivo*, 165
 Mercer SJ. *See* Knight LA, 649
 Mercier C. *See* Fanciullino R, 465
 Meyers RO. *See* Pourpak A, 1179
 Miano R. *See* Angelucci A, 1141
 Milano A *et al.* New molecular targeted therapies in thyroid cancer, 869
 Milano E *et al.* Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma, 1231
 Milano G. *See* Fanciullino R, 465; *also* Fischel J-L, 807
 Miller BR. *See* Nicholson B, 25
 Millimaggi D. *See* Angelucci A, 1141
 Mistr A. *See* Sova P, 201
 Miyake H. *See* Hara I, 1057
 Miyashita K. *See* Inoue T, 261
 Miyazaki T. *See* Fukuda Y, 943
 Moll I. *See* Freudlsperger C, 325
 Molucon-Chabrot C *et al.* Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis, 1211
 Monin-Baroille P. *See* Molucon-Chabrot C, 1211
 Mori T *et al.* Excretion of cytosine arabinoside in saliva after its administration at high doses, 597
 Moscheni C. *See* Gagliano N, 189
 Mössner J. *See* Wiedmann M, 783
 Mottet N. *See* Fléchon A, 705
 Mottolese M. *See* Nisticò C, 1193
 Mount J. *See* Bello CL, 353
 Mourelatos D. *See* Fouteris MA, 511
 Mousavi-Shafaei P *et al.* Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin, 1031
 Mousseau M. *See* Delozier T, 1067
 Mozaffar T. *See* Choi J, 103
 Mrhar A. *See* Piskur P, 719
 Muramatsu M. *See* Kanazawa S, 423
 Nakagawa S. *See* Aoki S, 269
 Nakahara H. *See* Nozaki S, 1109
 Nakano S. *See* Qin B, 439; *also* Qin B, 445
 Nakano T. *See* Inoue T, 261
 Nakao S. *See* Aoki S, 269
 Nakayama N. *See* Sasaki T, 581
 Nakazato T. *See* Mori T, 597
 Natoli G. *See* Nisticò C, 1193
 Navalón M. *See* Barceló R, 89
 Navas V. *See* Grande C, 1
 Neal LR. *See* Santen RJ, 33

- Némati F. *See* Decaudin D, 685
- Nersesyan A *et al.* Cytogenetic toxicity of cycloplata in human lymphocytes: detection by the micronucleus test and fluorescence *in situ* hybridization, 289
- Neumann R. *See* Hille S, 1041
- Neuteboom STC. *See* Nicholson B, 25
- Nicholson B *et al.* NPI-2358 is a tubulin-depolymerizing agent: *in vitro* evidence for activity as a tumor vascular-disrupting agent, 25
- Nicolantonio F. *See* Knight LA, 649
- Nikolaidou M. *See* Pappas P, 1185
- Nikolaropoulos SS. *See* Foustieris MA, 511
- Nisticò C *et al.* Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study, 345; *also* Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors, 1193
- Nolting D-M. *See* Lanvers-Kaminsky C, 1025
- Nomura S. *See* Kanazawa S, 423
- Nosi F. *See* Livi L, 1081
- Nottage M. *See* Duran I, 81
- Novelli F. *See* Nisticò C, 1193
- Nowicky W. *See* Gagliano N, 189
- Nozaki S *et al.* Targeting urokinase-type plasminogen activator and its receptor for cancer therapy, 1109
- Nygren P. *See* Dreilich M, 503
- Ochi Y. *See* Fukuda Y, 943
- Ochiai T. *See* Tsuruoka Y, 393
- Oehler L. *See* Wenzel C, 865
- Offen N. *See* Kirby R, 245
- Ogasawara Y. *See* Fujita T, 455
- Ohara T. *See* Nozaki S, 1109
- Okamoto S. *See* Mori T, 597
- Olbert PJ *et al.* Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel, 993
- Oldani S. *See* Ferrari D, 359
- O'Leary J. *See* Sewak S, 571
- Olsson-Strömberg U *et al.* Imatinib activity *in vitro* in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis, 631
- Oñate-Ocaña LF. *See* Fuentes H, 565
- Ono M. *See* Aoki S, 269
- Orlando L *et al.* Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer, 956
- Osti MF. *See* De Sanctis V, 967
- Otero J. *See* Fuentes H, 565
- Otrock ZK. *See* El-Saghir NS, 999
- Oudar O. *See* Ledoux D, 479
- Oza AM. *See* Duran I, 81
- Pagnotta E *et al.* N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells, 521
- Paier F. *See* Livi L, 1081
- Palladino MA. *See* Nicholson B, 25
- Palle J *et al.* Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia, 385; *also* Etoposide pharmacokinetics in children treated for acute myeloid leukemia, 1087
- Palma C. *See* Binaschi M, 1119
- Palmeri S. *See* Comella P, 985
- Palomares T *et al.* Influence of the level of γ -glutamyltranspeptidase activity on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to all-trans-retinoic acid, 1127
- Pampillón C. *See* Fichtner I, 333
- Panchal C. *See* Annabi B, 429
- Papageorgiou Athanasios. *See* Foustieris MA, 511
- Pappas P *et al.* Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine, 1185
- Park J-K. *See* Lee J-W, 377
- Park SH *et al.* Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil, 225
- Parlani M. *See* Binaschi M, 1119
- Paulsson-Karlsson Y. *See* Dreilich M, 503
- Paulussen M. *See* Wagner-Bohn A, 859
- Pavlidis N. *See* Briasoulis E, 1219
- Pérez-Victoria JM. *See* Ahmed-Belkacem A, 239
- Peillard L. *See* Fanciullino R, 465
- Pekalski M. *See* Fernando A, 913
- Pemberton K. *See* Cufer T, 401
- Perez L. *See* Fuentes H, 565
- Pérez-Castro AJ. *See* de Anta JM, 1171
- Perricaudet M. *See* Hosten B, 195
- Perrone E. *See* Nersesyan A, 289
- Perucchini D. *See* Fedier André, 315
- Peruzzi B. *See* Dharmawardana PG, 13
- Peruzzotti G. *See* Orlando L, 956; *also* Rocca A, 1201
- Peterson C. *See* Palle J, 385
- Petit T *et al.* Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer, 337
- Pezzullo L. *See* Milano A, 869
- Pfützner A. *See* Hille S, 1041
- Picci P. *See* Bacci G, 411
- Pietri E. *See* Rocca A, 1201
- Pinheiro JPV. *See* Wagner-Bohn A, 859
- Piovano M. *See* Russo A, 1163
- Piperidou C. *See* Briasoulis E, 1219
- Piskur P *et al.* Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective, 719
- Pistilli A. *See* Rende M, 929
- Plummer HK. *See* Cekanova M, 771
- Pöhland T *et al.* Bax and Bak are the critical complementary effectors of colorectal cancer cell apoptosis by chemopreventive resveratrol, 471
- Pond GR. *See* Duran I, 81
- Posey J. *See* Dobelbower MC, 95
- Poučková P. *See* Škvor J, 815
- Pouckova P. *See* Sova P, 201
- Poupon M-F. *See* Decaudin D, 685
- Pourpak A *et al.* Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice, 1179
- Pourroy B. *See* Bressin C, 181; *also* Milano E, 1231
- Powis G. *See* Engman L, 539
- Poyet C. *See* Fedier André, 315
- Pozza A. *See* Ahmed-Belkacem A, 239
- Praha C. *See* Fahrig R, 1045
- Preda L. *See* Orlando L, 956
- Preiss R *et al.* Plasma kinetics of procarbazine and azo-procarbazine in humans, 75
- Privot F-R. *See* Hebbar M, 855
- Putzu C. *See* Comella P, 985
- Qin B *et al.* In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose

- treatments in human squamous carcinoma cells, 439; *also* In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines, 445
- Qiu Q. *See* Merayo N, 165
- Quietzsch D. *See* Fahrig R, 1045
- Rabbani SA. *See* Annabi B, 429
- Rachid Z. *See* Merayo N, 165
- Raisch KP. *See* Dobelbower MC, 95
- Ramirez M. *See* Fuentes H, 565
- Ramos M. *See* Barceló R, 89
- Raymond MA. *See* Pourpak A, 1179
- Regenthal R. *See* Preiss R, 75
- Rein DT. *See* Hille S, 1041
- Ren K. *See* Liu X, 173
- Rende M *et al.* Role of nerve growth factor and its receptors in non-nervous cancer growth: efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: an in-vitro and in-vivo study, 929
- Rich JN. *See* Sathornsumetee S, 1003
- Rickardson L. *See* Dreilich M, 503
- Riffelmann M. *See* Hille S, 1041
- Rivera F. *See* Barceló R, 89
- Rocca A *et al.* A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer, 1209; *also see* Orlando L, 956
- Roemer K. *See* Pöhlend T, 471
- Roggieri P. *See* Nersesyan A, 289
- Romano O. *See* Hebbar M, 855
- Rome A. *See* Milano E, 1231
- Rosen EM. *See* Ma Y, 733
- Royer B. *See* Molucon-Chabrot C, 1211
- Rubinstein A. *See* Haupt S, 609
- Russo A *et al.* Pannarin inhibits cell growth and induces cell death in human prostate carcinoma DU-145 cells, 1163
- Russo S. *See* Wasif Saif M, 107
- Russo SM. *See* Dobelbower MC, 95
- Ryan C. *See* Beer TM, 1075
- Saif MW. *See* Gotlib V, 1227
- Saigenji K. *See* Sasaki T, 581
- Sainte-Catherine O. *See* Ledoux D, 479
- Sakamoto J *et al.* Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer, 231
- Sakamoto K. *See* Tsuruoka Y, 393
- Salbego C. *See* Braganhol E, 663
- Salvati M. *See* De Sanctis V, 967
- Salvatore C. *See* Binaschi M, 1119
- Samulitis BK. *See* Pourpak A, 1179
- Sandkötter J. *See* Lanvers-Kaminsky C, 1025
- Sandomenico C. *See* Comella P, 985
- Sanna P. *See* Rende M, 929
- Santen RJ *et al.* Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells, 33
- Santini R. *See* Livi L, 1081
- Sarangarajan R *et al.* Hypoxia-targeted bioreductive tyrosine kinase inhibitors with glutathione-depleting function, 21
- Sartorius J. *See* Hille S, 1041
- Sasaki T *et al.* TS-1 as first-line therapy for gastric linitis plastica: historical control study, 581
- Sastre J *et al.* UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors, 417
- Sathornsumetee S and Rich JN. New approaches to primary brain tumor treatment, 1003
- Savranskaya L. *See* Lothstein L, 495
- Scheithauer W. *See* Wenzel C, 865
- Schmid RM. *See* Fahrig R, 1045
- Schmidmaier R *et al.* Synergistic antimyeloma effects of zoledronate and simvastatin, 621
- Schmiegelow K. *See* Palle J, 385
- Schöndorf T. *See* Hille S, 1041
- Schrader AJ. *See* Olbert P, 993
- Schröder A. *See* Lanvers-Kaminsky C, 1025
- Schuller HM. *See* Cekanova M, 771
- Schumacher U. *See* Freudlsperger C, 325
- Schwarz C. *See* Wenzel C, 865
- Seay LL. *See* Dobelbower MC, 95
- Sellers S. *See* Wasif Saif M, 107
- Serin D. *See* Petit T, 337
- Serra M. *See* Bacci G, 411
- Sewak S *et al.* Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen, 571
- Seynhaeve ALB. *See* Hoving S, 949
- Sezer O. *See* Eucker J, 763
- Shan H-B *et al.* Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A, 905
- Shao R. *See* Liu X, 173
- Sharma S. *See* Knight LA, 649
- Sheikh S. *See* Chen P, 53
- Sherman L. *See* Bello CL, 353
- Sherry Chow H-H. *See* Pourpak A, 1179
- Shibata Y. *See* Qin B, 439; *also* Qin B, 445
- Shibuya M. *See* Aoki S, 269
- Shimizu N. *See* Fujita T, 455
- Shin DB. *See* Park SH, 225
- Shiraki K. *See* Inoue T, 261
- Shirasaka T. *See* Tsuruoka Y, 393
- Shord SS *et al.* Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer, 207
- Simon H. *See* Petit T, 337
- Simonsson B. *See* Olsson-Strömberg U, 631
- Simsek M. *See* Schmidmaier R, 621
- Siu LL. *See* Duran I, 81
- Škvor J. *et al.* Effect of wheat leaf ribonuclease on tumor cells and tissues, 815
- Slavík T. *See* Škvor J, 815
- Smeraglia J. *See* Bello CL, 353
- Smith J. *See* Fernando A, 913
- Smolewski P. *See* Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway, 487
- Socinski MA. *See* Hensing TA, 697
- Sonc M. *See* Piskur P, 719
- Song L. *See* Tang L, 297
- Sonntag D. *See* Fahrig R, 1045
- Soong R. *See* Budman DR, 921
- Sorich J. *See* Sewak S, 571
- Souček J. *See* Škvor J, 815
- Soulti K. *See* Briasoulis E, 1219
- Sova P *et al.* Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts, 201
- Spaeth D. *See* Petit T, 337
- Sparreboom A. *See* Lakhani N, 977
- Sperduti I. *See* Nisticò C, 345
- St John MAR *et al.* Recent new approaches to the treatment of head and neck cancer, 365
- Stabile A. *See* Rende M, 929
- Sterz J. *See* Eucker J, 763
- Stoffregen C. *See* Wagner-Bohn A, 859

- Strohfeldt K. *See* Fichtner I, 333
- Sturgeon J. *See* Duran I, 81
- Sugahara T. *See* Fukuda Y, 943
- Sugimoto K. *See* Inoue T, 261
- Suter S. *See* Dobelbower MC, 95
- Sweatman TW. *See* Lothstein L, 495
- Sweeney NJ. *See* Fichtner I, 333
- Tacke M. *See* Fichtner I, 333
- Tai J. *See* Budman DR, 921
- Takabatake D. *See* Fujita T, 455
- Takahashi H. *See* Fujita T, 455
- Takahashi N. *See* Takekuma M, 715
- Takakuwa R. *See* Takekuma M, 715
- Takekuma M *et al.* A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin, 715
- Takenaka A. *See* Hara I, 1057
- Talamonti MS. *See* Tong W-G, 1201
- Tamajusuku ASK. *See* Braganhol E, 663
- Tan Z. *See* Wang W, 797
- Tanabe S. *See* Sasaki T, 581
- Tanaka R. *See* Qin B, 439; *also* Qin B, 445
- Tang L *et al.* The principal urinary metabolites of dietary isothiocyanates, *N*-acetylcysteine conjugates, elicit the same anti-proliferative response as their parent compounds in human bladder cancer cells, 297
- Tannapfel A. *See* Wiedmann M, 783
- Tartaro T. *See* Ferrari D, 359
- Taylor CC. *See* Chen T, 123
- ten Hagen TLM. *See* Hoving S, 949
- Terashima M. *See* Sakamoto J, 231
- Terenzi A. *See* Rende M, 929
- Terzoli E. *See* Nisticò C, 345; *also* Nisticò C, 1193
- Théodore C. *See* Fléchon A, 705
- Thies A. *See* Freudlsperger C, 325
- Thompson DM. *See* Shord SS, 207
- Tian Z *et al.* Anti-cancer activity and mechanisms of 25-anhydrocimigenol-3-O- β -D-xylopyranoside isolated from *Souliea vaginata* on hepatomas, 545
- Tigaud J-D. *See* Petit T, 337
- Timmer-Bonte JNH and Tjan-Heijnen VCG. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors, 881
- Tjan-Heijnen VCG. *See* Timmer-Bonte JNH, 881
- To KKW *et al.* Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles, 673
- Tombolini V. *See* De Sanctis V, 967
- Tong Q-S *et al.* Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells, 279
- Torri C. *See* Gagliano N, 189
- Triboulet J-P. *See* Hebbar M, 855
- Tsujinaka T. *See* Sakamoto J, 231
- Tsukuda K. *See* Fujita T, 455
- Tsuruoka Y *et al.* Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1, 393
- Tzamakou E. *See* Briasoulis E, 1219
- Ueno M. *See* Fukuda Y, 943
- Ugolini G. *See* Rende M, 929
- Ugwu SO. *See* Sarangarajan R, 21
- Urbauer E. *See* Wenzel C, 865
- Vaccaro A *et al.* In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer, 849
- Valdes-Albini F. *See* Chow WA, 891
- Valentini A. *See* Angelucci A, 1141
- Valenza R. *See* Nisticò C, 345
- Valeriani M. *See* De Sanctis V, 967
- van Tiel ST. *See* Hoving S, 949
- Vanella L. *See* Russo A, 1163
- Vannetzel J-M. *See* Delozier T, 1067
- Vassilakos A. *See* Lee Y, 143
- Venitz J. *See* Lakhani N, 977
- Verkh L. *See* Bello CL, 353
- Veronesi P. *See* Rocca A, 1201
- Versari M. *See* Bacci G, 411
- Verweij J. *See* Engels FK, 63
- Viale G. *See* Rocca A, 1201
- Viau S. *See* Lee Y, 143
- Vicentini C. *See* Angelucci A, 1141
- Vincent-Salomon A. *See* Decaudin D, 685
- Vivanco G. *See* Barceló R, 89
- Vrdoljak E. *See* Cufer T, 401
- Wacrenier A. *See* Hebbar M, 855
- Wagenius G. *See* Dreilich M, 503
- Wagner S. *See* Pöhland T, 471
- Wagner-Bohn A *et al.* Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin, 859
- Wang B. *See* Shan H-b, 905
- Wang D. *See* Xiang D, 753
- Wang D-M *et al.* Cytotoxicity of a recombinant fusion protein of adenovirus early region 4 open reading frame 4 (E4orf4) and human epidermal growth factor on p53-deficient tumor cells, 527
- Wang L. *See* Tong Q-S, 279
- Wang M. *See* Lee Y, 143
- Wang W *et al.* Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721, 797
- Wang X. *See* Wang D-M, 527; *also* Wang W, 797
- Wang Y-J. *See* Kong W-J, 251
- Washio K. *See* Fujita T, 455
- Wasif Saif M *et al.* Gemcitabine-related radiation recall in a patient with pancreatic cancer, 107; *also* Peripheral neuropathy exacerbation associated with topical 5-fluorouracil, 1095
- Watabe S. *See* Tsuruoka Y, 393
- Watts RN. *See* Yu F, 1151
- Weiss M *et al.* Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery, 69
- Wenzel C *et al.* Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event, 865
- Whitehouse PA. *See* Knight LA, 649
- Wiedmann M *et al.* Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib, 783
- Wink MR. *See* Braganhol E, 663
- Woltering EA. *See* Kvols LK, 601
- Wong DTW. *See* St John MAR, 365
- Wright J. *See* Lee Y, 143
- Wu E. *See* Tian Z, 545
- Wu JJ. *See* Annabi B, 429
- Wu X. *See* Hasinoff BB, 825

- Wu X-H *et al.* Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion, 839
- Xian L-J. *See* Li J-L, 307; *also* Shan H-b, 905; *also* Li J-L, 1107
- Xiang D *et al.* Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the β -catenin/T-cell factor signaling, 753
- Xiao P. *See* Tian Z, 545
- Xie H-J. *See* Wang D-M, 527
- Xie J. *See* Xiang D, 753; *also* Xiang D, 753
- Xiong K. *See* Lee Y, 143
- Xu Z-l. *See* Shan H-b, 905
- Yalowich JC. *See* Hasinoff BB, 825
- Yamada Y. *See* Takekuma M, 715; *also* Hara I, 1057
- Yamaguchi K. *See* Kanazawa S, 423
- Yamaguchi Y. *See* Inoue T, 261
- Yamamichi G. *See* Takekuma M, 715
- Yamamoto E. *See* Nozaki S, 1109
- Yamamoto N. *See* Inoue T, 261
- Yamamura Y. *See* Sakamoto J, 231
- Yamanaka K. *See* Hara I, 1057
- Yamanaka Y. *See* Inoue T, 261
- Yamazaki R. *See* Mori T, 597
- Yang B. *See* He Q, 641
- Yang J. *See* Tian Z, 545
- Yang M. *See* Tian Z, 545
- Yang Y. *See* Wang W, 797
- Ying H. *See* He Q, 641
- Yoshizawa K. *See* Nozaki S, 1109
- You Q. *See* Wang W, 797
- Young A. *See* Lee Y, 143
- Yovine A. *See* Delozier T, 1067
- Yovine A. *See* Petit T, 337
- Yu F *et al.* Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells, 1151
- Yu J. *See* Wang W, 797
- Yuan R-q. *See* Ma Y, 733
- Yue W. *See* Santen RJ, 33
- Zadinova M. *See* Sova P, 201
- Zak F. *See* Sova P, 201
- Zamin LL. *See* Braganhol E, 663
- Zanetta S. *See* Molucon-Chabrot C, 1211
- Zang C. *See* Eucker J, 763
- Zangemeister-Wittke U. *See* Mousavi-Shafaei P, 1031
- Zannier F. *See* Ferrari D, 359
- Zavrski I. *See* Eucker J, 763
- Zazzi E-S. *See* Delozier T, 1067
- Zeng F-Q. *See* Tong Q-S, 279
- Zeng W-n. *See* Shan H-b, 905
- Zhang D. *See* Kong W-J, 251
- Zhang K. *See* Wang W, 797
- Zhang M. *See* Liu X, 173
- Zhang S. *See* Kong W-J, 251
- Zhang S-L. *See* Kong W-J, 251
- Zhang X. *See* Yu F, 1151
- Zhang Y. *See* Tang L, 297
- Zhao L. *See* Wang W, 797
- Zheng L-D. *See* Tong Q-S, 279
- Zhong Z. *See* Xiang D, 753
- Zhou H-J. *See* Wu X-H, 839
- Zhou J. *See* Bello CL, 353
- Zhou L. *See* Tian Z, 545
- Zhou Y. *See* Wang D-M, 527
- Ziaee A-A. *See* Mousavi-Shafaei P, 1031
- Zwaveling J *et al.* Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes, 1099